Skip to main content
Erschienen in: Breast Cancer Research 1/2014

Open Access 01.12.2014 | Poster presentation

PB.16. Breast screening mammograms: recall or not to recall. What is the golden ratio?

verfasst von: AR Sever, R Pietrosanu, J Weeks, P Mills

Erschienen in: Breast Cancer Research | Sonderheft 1/2014

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Introduction

The accuracy of prospectively categorised screening mammograms prior to assessment was evaluated and the individual recall and cancer detection rates for each category were studied.

Methods

The screening mammograms of women who attended the National Health Service Breast Screening Program over a period of 5 years (April 2008-March 2013) were included in the study. The recalled patients' films were prospectively categorised into one of six groups: patients with normal mammograms requiring clinical recall; probably benign; probably benign/suspicious; suspicious; suspicious/malignant; and malignant. Recalled patients were subsequently assessed with additional mammographic views, ± ultrasound and/or needle biopsy. The recall and cancer detection rates of each category were individually calculated.

Results

A total of 86,405 mammograms (17,881 prevalent and 68,524 incident rounds) were read and 4,125 patients were recalled for assessment (overall recall rate = 4.8%). A total of 721 patients were diagnosed with cancer (0.8%). The prevalent recall rate was 9.1% (recommended programme target <7%) and incident recall rate was 3.6% (target <5%).

Conclusion

Mammograms showing minimal signs of cancer that were categorised as 'probably benign' comprised the largest recall group with a relatively low detection rate (7%). If patient recall was limited to only more suspicious groups (that is, PB/suspicious and above), the overall recall rate would have dropped to 1% from 4.8%; however, 28% of the cancers would have missed. Patient anxiety generated due to false positive recalls and the cost of assessment clinics needs to be carefully balanced against a higher cancer detection rate.
Metadaten
Titel
PB.16. Breast screening mammograms: recall or not to recall. What is the golden ratio?
verfasst von
AR Sever
R Pietrosanu
J Weeks
P Mills
Publikationsdatum
01.12.2014
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe Sonderheft 1/2014
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3738

Weitere Artikel der Sonderheft 1/2014

Breast Cancer Research 1/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.